醛糖还原酶抑制剂依帕司他改善大鼠糖尿病膀胱病变组织的功能

Aldose reductase inhibitor epalrestat improves the structure and function of diabetic cystopathy in rat

目的研究醛糖还原酶(AR)、一氧化氮(NO)与糖尿病膀胱病(DCP)的关系,探讨醛糖还原酶抑制剂(ARIs)依帕司他对DCP的治疗作用。方法雄性SD大鼠60只分三组:正常组、糖尿病组和治疗组。测定膀胱组织AR活性,NO含量及一氧化氮合酶(NOS)活性。结果与正常组相比,糖尿病组膀胱组织内AR活性、NO含量和NOS活性升高(P<0.01),治疗组AR活性、NO含量和NOS活性均低于糖尿病组(P<0.05)。结论依帕司他通过抑制AR活性,调节NO含量变化及NOS活性,减轻氧化应激反应,改善膀胱组织的功能。

Objective To study the relationship of aldose reductase and nitric oxide with diabetic cystopathy as well as the treatment of diabetic cystopathy with aldose reductase inhibitor epalrestat. Methods 60 male SD rats were randomly assigned to three groups：healthy control,epalrestat treatment, diabetes. The bladder tissues were used for measurements of aldose reductase activity and the levels of nitric oxide, nitric oxide synthase. Results The diabetic rats had higher tissue aldose reductase activities,higher expression of the levels of nitric oxide and the nitric oxide synthase activity than healthy control（P〈0.01）. Epalrestat significantly reduced the tissue aldose reductase activities, the NO expression and the NOS activity of diabetic rats （P〈 0. 05）. Conclusions Epalrestat improves the bladder pathological dysfunctions by inhibiting the aldose reductase activities, and suppresses the apoptosis of the bladder cells by modulating the produce of NO and the activities of NOS.